
The AI-GUIDE device, developed by MIT Lincoln Laboratory and Massachusetts General Hospital, has won the 2026 Excellence in Technology Transfer Award. This portable medical device uses AI and handheld ultrasound technology to assist medics in performing critical interventions outside of hospital settings. The technology is being commercialized by AutonomUS Medical Technologies, a startup formed to bring AI-GUIDE to market. With FDA Breakthrough Device Designation, AI-GUIDE is set to enhance medical care for military personnel and civilians alike.
Read originalAI agents are advancing at a speed that European regulators are struggling to match, creating a significant challenge for oversight. The rapid pace of AI innovation is outstripping the ability of regulators to implement effective controls, raising concerns about potential risks. This situation demands more agile and responsive regulatory frameworks to keep pace with technological advancements. As AI agents become increasingly autonomous and capable, the urgency for effective regulation becomes more pronounced. The current gap between innovation and regulation underscores the need for swift action to ensure safety and ethical standards in AI development.
© The Verge AIThe recent agreement among AI leaders like OpenAI's Sam Altman and Google's Demis Hassabis to slow down AI development has sparked debate over their true intentions. While they claim to aim for safety by proposing third-party audits and global slowdown agreements, critics argue this could be a strategic move to stifle competition and control the narrative. The proposal, seen by some as a step towards responsible AI development, is also viewed with skepticism as a potential 'safety-washing' tactic. The real challenge lies in transforming these verbal commitments into enforceable actions that genuinely prioritize safety over market dominance.